The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Urination Disorders

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Urination Disorders


Psychiatry related information on Urination Disorders


High impact information on Urination Disorders

  • Nifedipine and nocturia [9].
  • Immediately after each episode of nocturia during the PSG, patients were questioned about the reason they believed they had awakened [10].
  • When patients were classified as responders or nonresponders in terms of bladder filling, urine flow, bladder emptying, weekly average of voids/24 hours, and nocturia, the proportion of patients responding to prazosin was significantly greater in all categories except bladder filling and emptying [11].
  • In randomised, double-blind trials in MS patients with nocturia, nasal desmopressin reduced the mean number of nocturnal voiding episodes by 31-54% [12].
  • RESULTS: In the nephrological group the incidence of high capacity bladder was 75%, residual urine 50%, UTI 43%, hesitancy 38%, intermittent flow 33%, bladder pain 33%, nighttime incontinence 29%, nocturia 24%, feeling of incomplete emptying 15%, daytime incontinence 14%, straining 14%, urgency 10%, burning sensation 10% and intermittency 5% [13].

Chemical compound and disease context of Urination Disorders

  • Beneficial effects of desmopressin on nocturia were maintained and increased in patients completing 10 or 12 months of further treatment in a nonblind extension of short-term trials [12].
  • To evaluate a novel approach to the symptomatic management of nocturia in patients with MS, we have conducted a trial of desmopressin acetate (1-desamino-8-D-arginine vasopressin), a synthetic analogue of antidiuretic hormone [3].
  • For a person to reach a 50% or greater reduction in nocturia, the advantage of terazosin over placebo was 17 percentage points [14].
  • This study was designed to investigate melatonin as a potential treatment for nocturia associated with bladder outflow obstruction in older men [15].
  • Maximum urinary flow, frequency and nocturia were unchanged during pinacidil treatment, compared to the initial test and the placebo period [16].

Biological context of Urination Disorders


Anatomical context of Urination Disorders

  • After clinical remission cyclophosphamide must be continued for at least a year under hydration sufficient to cause nycturia in order to protect the bladder mucosa [18].
  • The specific objectives were to study a) circadian changes in renal-endocrine function, including a comprehensive characterization of nocturia; b) cardiovascular-endocrine responses to a 90 degree tilt; c) erythrocyte functions, including intracellular organic phosphates and the Donnan ratio for chloride; and d) blood enzyme profiles [19].
  • OBJECTIVE: To investigate the number of tryptase positive bladder mast cells and the level of urine tryptase in interstitial cystitis (IC), a bladder disorder which occurs mostly in women and is characterized by suprapubic pain, frequency and nocturia [20].

Gene context of Urination Disorders

  • The only significant association of marker with symptom score was a positive correlation of IL-6 with nocturia [21].
  • Mean 24-hour micturition frequency decreased from 9.8 to 6.3 voids and nocturia decreased from 4.1 to 2.9 episodes nightly [22].
  • Moderate dysuria and difficulty in urinating were reported by 2-5% of patients treated with 3D CRT in contrast to 6-9% of patients treated with SRT; moderate urinary frequency and nocturia were reported by 18-24% treated with 3D CRT and 18-27% of patients in the SRT group [23].
  • Atrial natriuretic peptide levels in geriatric patients with nocturia and nursing home residents with nighttime incontinence [7].
  • More detailed physiologic studies are needed to understand better the pathophysiology of geriatric nocturia and nighttime incontinence and the role that AVP deficiency may play in these conditions [24].

Analytical, diagnostic and therapeutic context of Urination Disorders


  1. The clinical information value of the glycosylated hemoglobin assay. Nathan, D.M., Singer, D.E., Hurxthal, K., Goodson, J.D. N. Engl. J. Med. (1984) [Pubmed]
  2. Step II treatment with labetalol for essential hypertension. Bloomfield, S.S., Lucas, C.P., Gantt, C.L., Poland, M.P., Medakovic, M. Am. J. Med. (1983) [Pubmed]
  3. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Valiquette, G., Herbert, J., Maede-D'Alisera, P. Arch. Neurol. (1996) [Pubmed]
  4. Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia. Rembratt, A., Riis, A., Norgaard, J.P. Neurourology and urodynamics. (2006) [Pubmed]
  5. Efficacy of pentosan polysulfate in the treatment of interstitial cystitis: a meta-analysis. Hwang, P., Auclair, B., Beechinor, D., Diment, M., Einarson, T.R. Urology (1997) [Pubmed]
  6. Primary hyperparathyroidism in patients who have received radiation therapy and in patients who have not received radiation therapy. Tezelman, S., Rodriguez, J.M., Shen, W., Siperstein, A.E., Duh, Q.Y., Clark, O.H. J. Am. Coll. Surg. (1995) [Pubmed]
  7. Atrial natriuretic peptide levels in geriatric patients with nocturia and nursing home residents with nighttime incontinence. Ouslander, J., Johnson, T., Nasr, S., Schnelle, J., Miller, M. Journal of the American Geriatrics Society. (1999) [Pubmed]
  8. Desmopressin for nocturia and enuresis associated with multiple sclerosis. Ferreira, E., Letwin, S.R. The Annals of pharmacotherapy. (1998) [Pubmed]
  9. Nifedipine and nocturia. Mignot, G., Bernard, G., Chichmanian, R.M. Lancet (1988) [Pubmed]
  10. Nocturia. A rarely recognized symptom of sleep apnea and other occult sleep disorders. Pressman, M.R., Figueroa, W.G., Kendrick-Mohamed, J., Greenspon, L.W., Peterson, D.D. Arch. Intern. Med. (1996) [Pubmed]
  11. Alpha-adrenoceptor inhibitors in the treatment of benign prostatic hyperplasia. Kirby, R.S. Am. J. Med. (1989) [Pubmed]
  12. Desmopressin: in adults with nocturia. Cvetković, R.S., Plosker, G.L. Drugs (2005) [Pubmed]
  13. Lower urinary tract symptoms after renal transplantation in children. Van der Weide, M.J., Cornelissen, E.A., Van Achterberg, T., de Gier, R.P., Feitz, W.F. J. Urol. (2006) [Pubmed]
  14. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. Johnson, T.M., Jones, K., Williford, W.O., Kutner, M.H., Issa, M.M., Lepor, H. J. Urol. (2003) [Pubmed]
  15. Melatonin pharmacotherapy for nocturia in men with benign prostatic enlargement. Drake, M.J., Mills, I.W., Noble, J.G. J. Urol. (2004) [Pubmed]
  16. Effects of pinacidil on detrusor instability in men with bladder outlet obstruction. Hedlund, H., Mattiasson, A., Andersson, K.E. J. Urol. (1991) [Pubmed]
  17. Oral desmopressin for nocturnal polyuria in elderly subjects: a double-blind, placebo-controlled randomized exploratory study. Asplund, R., Sundberg, B., Bengtsson, P. BJU international. (1999) [Pubmed]
  18. Treatment of granulomatous disorders of the nose and paranasal sinuses. Andrassy, K., Rasmussen, N. Rhinology. (1989) [Pubmed]
  19. Seadragon VI: a 7-day dry saturation dive at 31 ATA. I. Objectives, design, and scope. Nakayama, H., Murai, T., Hong, S.K. Undersea biomedical research. (1987) [Pubmed]
  20. Elevated mast cell tryptase in the urine of patients with interstitial cystitis. Boucher, W., el-Mansoury, M., Pang, X., Sant, G.R., Theoharides, T.C. British journal of urology. (1995) [Pubmed]
  21. A comparison of multiple urine markers for interstitial cystitis. Erickson, D.R., Xie, S.X., Bhavanandan, V.P., Wheeler, M.A., Hurst, R.E., Demers, L.M., Kushner, L., Keay, S.K. J. Urol. (2002) [Pubmed]
  22. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. Kaplan, S.A., Walmsley, K., Te, A.E. J. Urol. (2005) [Pubmed]
  23. Three-dimensional conformal therapy or standard irradiation in localized carcinoma of prostate: preliminary results of a nonrandomized comparison. Perez, C.A., Michalski, J.M., Purdy, J.A., Wasserman, T.H., Williams, K., Lockett, M.A. Int. J. Radiat. Oncol. Biol. Phys. (2000) [Pubmed]
  24. Arginine vasopressin levels in nursing home residents with nighttime urinary incontinence. Ouslander, J.G., Nasr, S.Z., Miller, M., Withington, W., Lee, C.S., Wiltshire-Clement, M., Cruise, P., Schnelle, J.F. Journal of the American Geriatrics Society. (1998) [Pubmed]
  25. Intravesical capsaicin for treatment of severe bladder pain: a randomized placebo controlled study. Lazzeri, M., Beneforti, P., Benaim, G., Maggi, C.A., Lecci, A., Turini, D. J. Urol. (1996) [Pubmed]
  26. The risk of hyponatremia in older adults using desmopressin for nocturia: a systematic review and meta-analysis. Weatherall, M. Neurourology and urodynamics. (2004) [Pubmed]
  27. Diclofenac for treatment of nocturia caused by nocturnal polyuria: a prospective, randomised, double-blind, placebo-controlled crossover study. Addla, S.K., Adeyoju, A.B., Neilson, D., O'reilly, P. Eur. Urol. (2006) [Pubmed]
  28. Evaluation of a synthetic vasopressin analogue for treatment of nocturia in benign prostatic hypertrophy. A double-blind study. Månsson, W., Sundin, T., Gullberg, B. Scandinavian journal of urology and nephrology. (1980) [Pubmed]
WikiGenes - Universities